United Therapeutics (UTHR)CEO sold ~$57K

~$57K

Approx. value · 107 sh @ $531.08

41K

Holds after · shares reported

Traded

Jul 14, 2026

Filed

Jul 16, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 13, 2026Insider · 1 personInsiders: 9 sales (~$5.5M)
2. May 14, 2026Insider · 2 peopleInsiders: 19 sales (~$11.2M)
3. May 15, 2026Insider · 1 personInsiders: 7 sales (~$5.4M)
4. May 18, 2026Insider · 2 peopleInsiders: 16 sales (~$11.1M)
5. May 19, 2026Insider · 1 personInsiders: 10 sales (~$5.4M)
6. May 20, 2026Insider · 1 personInsiders: 13 sales (~$5.4M)
7. May 21, 2026Insider · 1 personInsiders: 6 sales (~$2.5M)
8. Jun 26, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“As described in Item 5.07 below, on June 26, 2026, at the 2026 Annual Meeting of Shareholders of United Therapeutics Corporation (the Company ), the Company’s shareholders approved the United Therapeutics Corporation 2026 Stock Incentive Plan (the 2026 Plan ).”

What came next

1. Jul 22, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On July 22, 2026, the Board of Directors (the Board ) of United Therapeutics Corporation (the Company ), acting upon the recommendation of its Nominating and Governance Committee, increased the size of the Board to 13 members and appointed Victor Dzau, M.D., to serve as a member of the Board.”
2. Aug 5, 2026Company filing · Form 8-K · ResultsReported its results
3. Sep 8, 2026Company filing · Form 8-K · Material agreement, Reg FDSigned an important agreement, and shared information with investors

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for United Therapeutics

For United Therapeutics, OQRO holds 791 insider filings (SEC Form 4 or Form 144), 18 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its UTHR page.

Other recent filings by Martine A Rothblatt, Chairperson & CEO

• SEC Form 4 at United Therapeutics (UTHR)Oct 9, 2026
• SEC Form 4 at United Therapeutics (UTHR)Oct 9, 2026
• SEC Form 4 at United Therapeutics (UTHR)Oct 9, 2026
• SEC Form 4 at United Therapeutics (UTHR)Oct 9, 2026
• SEC Form 4 at United Therapeutics (UTHR)Oct 9, 2026

The full history of Martine A Rothblatt, Chairperson & CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at United Therapeutics

• SEC Form 4Oct 9, 2026
• SEC Form 4Oct 9, 2026
• SEC Form 4Oct 9, 2026
• SEC Form 4Oct 9, 2026
• SEC Form 4Oct 9, 2026
• SEC Form 4Oct 9, 2026

Everything OQRO holds on this company is on its UTHR page.